Verition Fund Management
VERV

Verition Fund Management’s Verve Therapeutics VERV Stock Holding History

Verition Fund Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15,339
Closed -$86.5K – 3741
2024
Q4 		$86.5K Sell
15,339
-13,375
-47% -$75.4K ﹤0.01% 3093
2024
Q3 		$139K Buy
+28,714
New +$167K ﹤0.01% 2956
2023
Q3 		– Sell
-27,153
Closed -$509K – 2701
2023
Q2 		$509K Sell
27,153
-2,513
-8% -$41.9K 0.01% 1234
2023
Q1 		$428K Buy
+29,666
New +$581K 0.01% 1334

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Verition Fund Management's VERV Position: Q1 2025 in Review

Verition Fund Management sold out of Verve Therapeutics (VERV) in Q1 2025, closing a stake of 15,339 shares — an estimated $86.5K sold.

Verition Fund Management first reported a position in VERV in Q1 2023 and held it in 4 quarters. The position peaked at $509K in Q2 2023. 191 funds tracked by Wall St. Rank hold VERV as of Q1 2025.

  • Verition Fund Management reported no remaining Verve Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Verition Fund Management sold 15,339 Verve Therapeutics shares in Q1 2025, an estimated $86.5K.
  • Verition Fund Management first reported a position in Verve Therapeutics in Q1 2023 and held it in 4 quarters.
  • Verition Fund Management's Verve Therapeutics position peaked at $509K in Q2 2023.
  • 191 funds tracked by Wall St. Rank held Verve Therapeutics as of Q1 2025.

Based on Verition Fund Management's 13F filing for Q1 2025, filed 15 May 2025.